Cargando…
Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review
Radioligand therapy with Lutetium-177 (177Lu)-Prostate-specific membrane antigen (PSMA) has shown to prolong survival in metastatic castration resistant prostate cancer (mCRPC). One of the major challenges for clinicians in the future is to select those patients who would benefit most from this ther...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902011/ https://www.ncbi.nlm.nih.gov/pubmed/35273651 http://dx.doi.org/10.1177/17588359221081922 |
_version_ | 1784664497834688512 |
---|---|
author | Heidegger, Isabel Kesch, Claudia Kretschmer, Alexander Tsaur, Igor Ceci, Francesco Valerio, Massimo Tilki, Derya Marra, Giancarlo Preisser, Felix Fankhauser, Christian D. Zattoni, Fabio Chiu, Peter Puche-Sanz, Ignacio Olivier, Jonathan van den Bergh, Roderik C. N. Kasivisvanathan, Veeru Pircher, Andreas Virgolini, Irene Gandaglia, Giorgio |
author_facet | Heidegger, Isabel Kesch, Claudia Kretschmer, Alexander Tsaur, Igor Ceci, Francesco Valerio, Massimo Tilki, Derya Marra, Giancarlo Preisser, Felix Fankhauser, Christian D. Zattoni, Fabio Chiu, Peter Puche-Sanz, Ignacio Olivier, Jonathan van den Bergh, Roderik C. N. Kasivisvanathan, Veeru Pircher, Andreas Virgolini, Irene Gandaglia, Giorgio |
author_sort | Heidegger, Isabel |
collection | PubMed |
description | Radioligand therapy with Lutetium-177 (177Lu)-Prostate-specific membrane antigen (PSMA) has shown to prolong survival in metastatic castration resistant prostate cancer (mCRPC). One of the major challenges for clinicians in the future is to select those patients who would benefit most from this therapy to position it in the treatment landscape of mCRPC. This, in turn, will lead to the delivery of personalized therapies. In this narrative review article we summarize recent studies investigating both predictive and prognostic clinical, imaging-based, and molecular biomarkers to predict treatment response to 177Lu-PSMA-617 radioligand therapy with the aim of identifying men who should be considered for this approach. Of note, the evidence on the role of biomarkers currently relies on small retrospective trials and their validation in larger prospective cohorts is necessary before these results can be translated in the clinical practice. |
format | Online Article Text |
id | pubmed-8902011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-89020112022-03-09 Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review Heidegger, Isabel Kesch, Claudia Kretschmer, Alexander Tsaur, Igor Ceci, Francesco Valerio, Massimo Tilki, Derya Marra, Giancarlo Preisser, Felix Fankhauser, Christian D. Zattoni, Fabio Chiu, Peter Puche-Sanz, Ignacio Olivier, Jonathan van den Bergh, Roderik C. N. Kasivisvanathan, Veeru Pircher, Andreas Virgolini, Irene Gandaglia, Giorgio Ther Adv Med Oncol Review Radioligand therapy with Lutetium-177 (177Lu)-Prostate-specific membrane antigen (PSMA) has shown to prolong survival in metastatic castration resistant prostate cancer (mCRPC). One of the major challenges for clinicians in the future is to select those patients who would benefit most from this therapy to position it in the treatment landscape of mCRPC. This, in turn, will lead to the delivery of personalized therapies. In this narrative review article we summarize recent studies investigating both predictive and prognostic clinical, imaging-based, and molecular biomarkers to predict treatment response to 177Lu-PSMA-617 radioligand therapy with the aim of identifying men who should be considered for this approach. Of note, the evidence on the role of biomarkers currently relies on small retrospective trials and their validation in larger prospective cohorts is necessary before these results can be translated in the clinical practice. SAGE Publications 2022-03-05 /pmc/articles/PMC8902011/ /pubmed/35273651 http://dx.doi.org/10.1177/17588359221081922 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Heidegger, Isabel Kesch, Claudia Kretschmer, Alexander Tsaur, Igor Ceci, Francesco Valerio, Massimo Tilki, Derya Marra, Giancarlo Preisser, Felix Fankhauser, Christian D. Zattoni, Fabio Chiu, Peter Puche-Sanz, Ignacio Olivier, Jonathan van den Bergh, Roderik C. N. Kasivisvanathan, Veeru Pircher, Andreas Virgolini, Irene Gandaglia, Giorgio Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review |
title | Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review |
title_full | Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review |
title_fullStr | Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review |
title_full_unstemmed | Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review |
title_short | Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review |
title_sort | biomarkers to personalize treatment with 177lu-psma-617 in men with metastatic castration-resistant prostate cancer - a state of the art review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902011/ https://www.ncbi.nlm.nih.gov/pubmed/35273651 http://dx.doi.org/10.1177/17588359221081922 |
work_keys_str_mv | AT heideggerisabel biomarkerstopersonalizetreatmentwith177lupsma617inmenwithmetastaticcastrationresistantprostatecancerastateoftheartreview AT keschclaudia biomarkerstopersonalizetreatmentwith177lupsma617inmenwithmetastaticcastrationresistantprostatecancerastateoftheartreview AT kretschmeralexander biomarkerstopersonalizetreatmentwith177lupsma617inmenwithmetastaticcastrationresistantprostatecancerastateoftheartreview AT tsaurigor biomarkerstopersonalizetreatmentwith177lupsma617inmenwithmetastaticcastrationresistantprostatecancerastateoftheartreview AT cecifrancesco biomarkerstopersonalizetreatmentwith177lupsma617inmenwithmetastaticcastrationresistantprostatecancerastateoftheartreview AT valeriomassimo biomarkerstopersonalizetreatmentwith177lupsma617inmenwithmetastaticcastrationresistantprostatecancerastateoftheartreview AT tilkiderya biomarkerstopersonalizetreatmentwith177lupsma617inmenwithmetastaticcastrationresistantprostatecancerastateoftheartreview AT marragiancarlo biomarkerstopersonalizetreatmentwith177lupsma617inmenwithmetastaticcastrationresistantprostatecancerastateoftheartreview AT preisserfelix biomarkerstopersonalizetreatmentwith177lupsma617inmenwithmetastaticcastrationresistantprostatecancerastateoftheartreview AT fankhauserchristiand biomarkerstopersonalizetreatmentwith177lupsma617inmenwithmetastaticcastrationresistantprostatecancerastateoftheartreview AT zattonifabio biomarkerstopersonalizetreatmentwith177lupsma617inmenwithmetastaticcastrationresistantprostatecancerastateoftheartreview AT chiupeter biomarkerstopersonalizetreatmentwith177lupsma617inmenwithmetastaticcastrationresistantprostatecancerastateoftheartreview AT puchesanzignacio biomarkerstopersonalizetreatmentwith177lupsma617inmenwithmetastaticcastrationresistantprostatecancerastateoftheartreview AT olivierjonathan biomarkerstopersonalizetreatmentwith177lupsma617inmenwithmetastaticcastrationresistantprostatecancerastateoftheartreview AT vandenberghroderikcn biomarkerstopersonalizetreatmentwith177lupsma617inmenwithmetastaticcastrationresistantprostatecancerastateoftheartreview AT kasivisvanathanveeru biomarkerstopersonalizetreatmentwith177lupsma617inmenwithmetastaticcastrationresistantprostatecancerastateoftheartreview AT pircherandreas biomarkerstopersonalizetreatmentwith177lupsma617inmenwithmetastaticcastrationresistantprostatecancerastateoftheartreview AT virgoliniirene biomarkerstopersonalizetreatmentwith177lupsma617inmenwithmetastaticcastrationresistantprostatecancerastateoftheartreview AT gandagliagiorgio biomarkerstopersonalizetreatmentwith177lupsma617inmenwithmetastaticcastrationresistantprostatecancerastateoftheartreview |